Conditions: Infectious Mononucleosis
Keywords: Mono Mononucleosis Epstein-Barr virus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 23
Healthy volunteers: no

Brief summary:
This will be a randomized, placebo-controlled, double-blind single-center proof of concept study to evaluate the anti-EBV activity of 4 grams of valomaciclovir (2 grams BID) for 21 days in subjects with infectious mononucleosis documented to be caused by primary EBV infection. Otherwise healthy subjects (≥15 years old) referred to us with a clinical diagnosis of primary infectious mononucleosis will be screened and those with laboratory-confirmed primary EBV infection will be enrolled.

Detailed description:
Subjects will be seen 2 times a week for 3 weeks and then weekly for 3 weeks. Clinical findings, clinical lab tests, EBV viral loads, and EBV antibody titers will be obtained at each clinic visit.

Arms:
arm 1: Valomaciclovir 2 grams orally twice daily for 21 days arm 2: placebo 2 tablets twice daily for 21 days

Interventions: intervention 1: Valomaciclovir intervention 2: placebo
Intervention descriptions: intervention 1: 4 grams orally of valomaciclovir (2 grams BID) for 21 days. intervention 2: Placebo tablets orally twice daily for 21 days.

Protocol document: